The test, developed with Pfizer, could identify renal cancer patients who would experience recurrence, but not who would benefit from adjuvant Sutent.
The initial FDA approval of Thermo Fisher's NGS panel test for personalizing cancer treatment may allow rapid expansion to new indications.
The so-called universal CDx approved by the FDA can gauge alterations across multiple genes associated with response to three lung cancer treatments.
Guardant will provide its Guardant360 liquid biopsy cancer assay to Pfizer's oncology business unit for use in clinical trials.
Collaborators have created an atlas that compares available PD-L1 IHC assays and reveals areas of debate, including challenges encountered by clinicians.
The company has also announced a collaboration with Pfizer to develop a blood-based assay to identify critical-stage cardiometabolic conditions.
Thermo Fisher developed the NGS-based multi-marker assay in collaboration with Novartis and Pfizer to match lung cancer patients with targeted drugs.
The companies discussed their plans to change the one-test, one-drug companion diagnostic paradigm at the Personalized and Precision Medicine conference this week.